The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×2•Originally published 7 March 2026•Updated 8 March 2026•

1 min read

Hims & Hers Shares Skyrocket 40% on Surprise Novo Nordisk Settlement for Wegovy Distribution

Key Facts

1Novo Nordisk plans to sell its weight-loss drug Wegovy on the Hims & Hers Health platform.

3 months ago

Version History

Version 23 months ago

What changed: Updated to include the 40% surge in Hims & Hers share price and the timing of the market reaction late Friday.

Version 13 months ago

What changed: Update confirms the sharp rally in Hims & Hers shares and the element of surprise the deal presented to investors.

Hims & Hers Health shares skyrocketed 40% late Friday following the announcement of a legal settlement and strategic partnership with Novo Nordisk. The agreement allows Novo Nordisk to distribute its popular weight-loss medication, Wegovy, through the Hims & Hers digital platform. This surprise move effectively ends a legal battle that had previously weighed on both companies' stock performance, removing a significant layer of uncertainty for investors. The partnership provides Novo Nordisk with a massive new distribution channel to meet the surging global demand for GLP-1 treatments. Market analysts view the shift from litigation to revenue-generating collaboration as a major validation of the Hims & Hers telehealth model. The deal is expected to significantly impact the financial outlook of both entities within the rapidly expanding obesity drug market.